Cargando…

SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors

Detalles Bibliográficos
Autores principales:	Frieman, Matthew, Harris, Anthony D., Herati, Ramin Sedaghat, Krammer, Florian, Mantovani, Alberto, Rescigno, Maria, Sajadi, Mohammad M., Simon, Viviana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149267/ https://www.ncbi.nlm.nih.gov/pubmed/34051441 http://dx.doi.org/10.1016/j.ebiom.2021.103401

Ejemplares similares

Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
por: Samanovic, Marie I., et al.
Publicado: (2021)

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
por: Samanovic, Marie I., et al.
Publicado: (2021)

Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines
por: Samanovic, Marie I., et al.
Publicado: (2022)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

SARS-CoV-2 Vaccines: Status Report
por: Amanat, Fatima, et al.
Publicado: (2020)

SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants
por: Kubale, John, et al.
Publicado: (2022)

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals
por: Sano, Kaori, et al.
Publicado: (2022)

Multimodal characterization of antigen-specific CD8(+) T cells across SARS-CoV-2 vaccination and infection
por: Zhang, Bingjie, et al.
Publicado: (2023)

High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
por: Tada, Takuya, et al.
Publicado: (2022)

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
por: Van Oekelen, Oliver, et al.
Publicado: (2021)

Multimodal single-cell datasets characterize antigen-specific CD8(+) T cells across SARS-CoV-2 vaccination and infection
por: Zhang, Bingjie, et al.
Publicado: (2023)

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
por: Aleman, Adolfo, et al.
Publicado: (2022)

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
por: Tada, Takuya, et al.
Publicado: (2021)

Correlates of protection from SARS-CoV-2 infection
por: Krammer, Florian
Publicado: (2021)

Association Between Duration of SARS-CoV-2 Positivity and Long COVID
por: Pozzi, Chiara, et al.
Publicado: (2023)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
por: Jangra, Sonia, et al.
Publicado: (2021)

SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors
por: Duan, Li-Jun, et al.
Publicado: (2022)

The continued epidemic threat of SARS-CoV-2 and implications for the future of global public health
por: Sheahan, Timothy P, et al.
Publicado: (2020)

Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays
por: Rikhtegaran Tehrani, Zahra, et al.
Publicado: (2020)

Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain
por: Altomare, Clara G., et al.
Publicado: (2022)

Routine SARS‐CoV‐2 vaccination for all children
por: De Paris, Kristina, et al.
Publicado: (2022)

Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays
por: Tehrani, Zahra Rikhtegaran, et al.
Publicado: (2020)

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
por: Rescigno, Maria, et al.
Publicado: (2023)

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
por: Lipsitch, Marc, et al.
Publicado: (2021)

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
por: Krammer, Florian, et al.
Publicado: (2021)

Phylogenetic analysis and comparative genomics of SARS-CoV-2 from survivor and non-survivor COVID-19 patients in Cordoba, Argentina
por: Olivero, Nadia B., et al.
Publicado: (2022)

Effects of Second Dose of SARS-CoV-2 Vaccination on Household Transmission, England
por: Zaidi, Asad, et al.
Publicado: (2023)

Inhibition of the IFN-α JAK/STAT Pathway by MERS-CoV and SARS-CoV-1 Proteins in Human Epithelial Cells
por: Zhang, Yamei, et al.
Publicado: (2022)

Localized Hepatosplenic Sarcoidosis with an Elevated Serum CA-125 Level
por: Herati, Ramin S., et al.
Publicado: (2010)

Adverse Events to Comirnaty Vaccine Are Linked to Sex, Age and BMI: Should We Consider Reducing the Dose for Females?
por: Azzolini, Elena, et al.
Publicado: (2023)

Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
por: Kogan Zajdman, Ariel, et al.
Publicado: (2022)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients
por: Levi, Riccardo, et al.
Publicado: (2021)

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
por: Aleman, Adolfo, et al.
Publicado: (2021)

Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
por: Lu, Bi-Nan, et al.
Publicado: (2022)

Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate
por: Naseripour, Masood, et al.
Publicado: (2016)

Equitable and Feasible Distribution of SARS-CoV-2 Vaccines for All in Africa
por: Rogers, Abu Bakarr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_707d8sopqeea4k1obvql7uo5gc